Could very high LDL mean I have familial hypercholesterolemia?

Very high LDL cholesterol (above 190 mg/dL in adults or 160 mg/dL in children) could indicate familial hypercholesterolemia, a genetic condition affecting 1 in 250 people. Early diagnosis through blood tests and genetic screening is crucial for preventing heart disease.

Questions on this topic?Ask Sai, our AI longevity expert.
Ask Sai

If your recent blood test showed very high LDL cholesterol levels, you might be wondering whether this could be more than just a diet and lifestyle issue. For some people, extremely elevated LDL cholesterol points to familial hypercholesterolemia (FH), a genetic condition that affects how your body processes cholesterol. Understanding whether your high LDL is due to FH is crucial because this condition significantly increases your risk of early heart disease and requires specific treatment approaches.

Familial hypercholesterolemia affects approximately 1 in 250 people worldwide, making it one of the most common genetic disorders. Despite its prevalence, it remains vastly underdiagnosed, with studies suggesting that up to 90% of people with FH don't know they have it. This article will help you understand when very high LDL might indicate FH, how to get properly diagnosed, and what steps you can take to protect your cardiovascular health.

Understanding Familial Hypercholesterolemia

Familial hypercholesterolemia is an inherited disorder that impairs your body's ability to remove LDL cholesterol from your blood. This happens due to mutations in genes responsible for cholesterol metabolism, most commonly the LDL receptor gene. When these receptors don't work properly, LDL cholesterol accumulates in your bloodstream, leading to levels that are typically much higher than what lifestyle factors alone would cause.

LDL Cholesterol Levels and FH Risk

LDL Level (mg/dL)AdultsChildrenClinical Significance
<100<100OptimalOptimalLow cardiovascular risk
100-129100-129Near optimalAcceptableSlightly elevated risk
130-159130-159Borderline highBorderline highModerate risk, lifestyle changes recommended
160-189160-189HighHigh, possible FHHigh risk, medication often needed
≥190≥190Very high, suspect FHVery high, likely FHEvaluate for FH, immediate treatment needed

LDL thresholds for suspecting familial hypercholesterolemia differ between adults and children.

There are two forms of FH: heterozygous FH (HeFH), where you inherit one mutated gene from one parent, and homozygous FH (HoFH), where you inherit mutated genes from both parents. HeFH is more common, affecting about 1 in 250 people, while HoFH is rare but more severe, affecting approximately 1 in 160,000 to 1 in 300,000 people. The type you have dramatically impacts your cholesterol levels and cardiovascular risk.

The Genetic Component

FH follows an autosomal dominant inheritance pattern, meaning you only need to inherit one copy of the mutated gene to have the condition. If one parent has FH, each child has a 50% chance of inheriting it. The most common mutations affect the LDLR gene (60-80% of cases), but mutations in APOB and PCSK9 genes can also cause FH. These genes all play crucial roles in how your body clears LDL cholesterol from the bloodstream.

When to Suspect Familial Hypercholesterolemia

Very high LDL cholesterol is the primary red flag for FH, but specific thresholds help distinguish FH from lifestyle-related high cholesterol. Understanding these levels and recognizing other signs can help you determine whether genetic testing might be warranted.

LDL Cholesterol Thresholds

For adults, an untreated LDL cholesterol level above 190 mg/dL should raise suspicion for FH. In children, the threshold is lower at 160 mg/dL. However, people with FH often have much higher levels, with heterozygous FH typically causing LDL levels between 190-400 mg/dL, and homozygous FH often resulting in levels exceeding 400 mg/dL. These levels persist despite healthy lifestyle choices and are present from birth.

Physical Signs and Family History

Beyond blood tests, FH can manifest through physical signs, though not everyone with FH develops them. These include cholesterol deposits in tendons (tendon xanthomas), particularly the Achilles tendon, cholesterol deposits around the eyes (xanthelasmas), and a grayish-white arc around the cornea (corneal arcus) in people under 45. A strong family history of high cholesterol, early heart disease (before age 55 in men or 65 in women), or sudden cardiac death in relatives also suggests possible FH.

Getting Diagnosed: Tests and Criteria

Diagnosing FH involves a combination of cholesterol testing, clinical evaluation, and often genetic testing. Healthcare providers use established criteria to assess the likelihood of FH based on your cholesterol levels, physical signs, and family history. Early and accurate diagnosis is essential for preventing cardiovascular complications.

Diagnostic Criteria

Several diagnostic tools help identify FH, including the Dutch Lipid Clinic Network criteria, Simon Broome criteria, and the Make Early Diagnosis to Prevent Early Deaths (MEDPED) criteria. These scoring systems consider your LDL cholesterol level, presence of tendon xanthomas, family history of high cholesterol or early heart disease, and genetic test results. A score above certain thresholds indicates definite, probable, or possible FH.

Regular cholesterol monitoring is crucial for managing FH and assessing treatment effectiveness. Home testing can make this process more convenient and help you track your progress between doctor visits.

Genetic Testing

Genetic testing can confirm an FH diagnosis by identifying specific mutations in the LDLR, APOB, or PCSK9 genes. While not always necessary for diagnosis, genetic testing is particularly valuable for family screening, as it allows relatives to be tested for the same mutation. This cascade screening approach helps identify affected family members early, often before they develop cardiovascular complications.

Why Early Detection Matters

People with untreated FH face a significantly elevated risk of premature cardiovascular disease. Without treatment, men with heterozygous FH have a 50% chance of having a heart attack by age 50, while women face the same risk by age 60. The risk is even higher for those with homozygous FH, who can experience heart attacks in childhood or adolescence. This accelerated atherosclerosis occurs because high LDL levels from birth lead to cumulative cholesterol exposure over decades.

However, early diagnosis and treatment can dramatically change these outcomes. Studies show that people with FH who are diagnosed and treated early can achieve near-normal life expectancy. Treatment typically reduces cardiovascular risk by 80% or more, highlighting why identifying FH as soon as possible is critical. This is particularly important for children with FH, as starting treatment in childhood can prevent decades of cholesterol accumulation.

Treatment Approaches for Familial Hypercholesterolemia

Managing FH requires a more aggressive approach than typical high cholesterol. While lifestyle modifications remain important, medication is almost always necessary to achieve safe LDL levels. The goal is to reduce LDL cholesterol by at least 50% from baseline and ideally reach levels below 100 mg/dL (or below 70 mg/dL for those with existing cardiovascular disease).

Medication Options

High-intensity statins form the foundation of FH treatment, often started at maximum tolerated doses. Common options include atorvastatin (40-80 mg) or rosuvastatin (20-40 mg). However, statins alone rarely achieve target LDL levels in FH patients. Additional medications often include ezetimibe, which blocks cholesterol absorption in the intestines, and PCSK9 inhibitors (evolocumab or alirocumab), injectable medications that can lower LDL by an additional 50-60%. For homozygous FH, newer treatments like lomitapide or mipomersen may be necessary.

Lifestyle Modifications

While medication is essential for FH, lifestyle changes still play a supportive role. A heart-healthy diet low in saturated fat and cholesterol can provide modest additional LDL reduction. Regular exercise, maintaining a healthy weight, avoiding smoking, and managing other cardiovascular risk factors like blood pressure and diabetes become even more critical when you have FH. These modifications work synergistically with medications to reduce overall cardiovascular risk.

Living with Familial Hypercholesterolemia

A diagnosis of FH can feel overwhelming, but with proper management, most people with FH can live long, healthy lives. Success requires consistent medication adherence, regular monitoring, and ongoing communication with your healthcare team. Many people find that understanding their condition empowers them to take control of their cardiovascular health.

Regular monitoring becomes a cornerstone of FH management. This includes cholesterol testing every 3-6 months initially, then annually once stable on treatment. Additional cardiovascular assessments like carotid ultrasounds or coronary calcium scans may help track atherosclerosis progression. Monitoring for medication side effects and adjusting treatment as needed ensures optimal outcomes.

Family screening represents another crucial aspect of living with FH. Since FH is genetic, first-degree relatives (parents, siblings, children) should be tested. Cascade screening can identify affected family members early, often before any symptoms develop. Children of FH parents should be screened by age 2, as early treatment provides the greatest benefit. Genetic counseling can help families understand inheritance patterns and make informed decisions.

Taking Action: Next Steps If You Suspect FH

If your LDL cholesterol is very high, don't wait to take action. Start by scheduling an appointment with your healthcare provider to discuss your cholesterol levels and family history. Bring any previous cholesterol test results and create a family tree noting any relatives with high cholesterol, heart attacks, strokes, or sudden cardiac death, especially at young ages.

Ask your provider about FH screening using established diagnostic criteria. If FH seems likely, request a referral to a lipid specialist who has expertise in managing genetic cholesterol disorders. These specialists can optimize your treatment plan and coordinate genetic testing if appropriate. Remember that FH is a manageable condition, and early diagnosis and treatment can help you maintain excellent cardiovascular health throughout your life.

Consider joining FH support groups or organizations like the FH Foundation, which provide resources, education, and community for people living with FH. These groups can help you navigate insurance coverage for medications, find FH specialists, and connect with others managing the same condition. With the right knowledge, treatment, and support, a diagnosis of FH becomes not a limitation but a roadmap to protecting your heart health.

References

  1. Nordestgaard, B. G., Chapman, M. J., Humphries, S. E., et al. (2013). Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. European Heart Journal, 34(45), 3478-3490.[Link][DOI]
  2. Goldberg, A. C., Hopkins, P. N., Toth, P. P., et al. (2011). Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients. Journal of Clinical Lipidology, 5(3), S1-S8.[Link][DOI]
  3. Knowles, J. W., Rader, D. J., & Khoury, M. J. (2017). Cascade screening for familial hypercholesterolemia and the use of genetic testing. JAMA, 318(4), 381-382.[Link][DOI]

Frequently Asked Questions

How can I test my LDL cholesterol at home?

You can test your LDL cholesterol at home with SiPhox Health's Heart & Metabolic Program. This CLIA-certified program includes comprehensive lipid testing including LDL, HDL, triglycerides, and advanced markers like ApoB, providing lab-quality results from the comfort of your home.

What LDL level indicates possible familial hypercholesterolemia?

In adults, an untreated LDL cholesterol level above 190 mg/dL suggests possible FH. For children, the threshold is 160 mg/dL. However, many people with FH have much higher levels, often between 190-400 mg/dL for heterozygous FH.

Can familial hypercholesterolemia be cured?

FH cannot be cured since it's a genetic condition, but it can be effectively managed with medications and lifestyle changes. With proper treatment, people with FH can achieve near-normal life expectancy and significantly reduce their cardiovascular risk.

Should my family members be tested if I have FH?

Yes, all first-degree relatives (parents, siblings, children) should be tested if you have FH. Since FH is inherited, each first-degree relative has a 50% chance of having the condition. Early detection through cascade screening can prevent heart disease.

What's the difference between high cholesterol and familial hypercholesterolemia?

Regular high cholesterol is usually caused by diet, lifestyle, and age, while FH is a genetic condition present from birth. FH causes much higher LDL levels that don't respond well to lifestyle changes alone and requires lifelong medication management.

Related Articles

This article is licensed under CC BY 4.0. You are free to share and adapt this material with attribution.

Ask Questions About Any Health Topic

Chat with Sai, our AI health assistant, for personalized insights.

Click or drag file to upload blood test results

Backed By Leading Experts in Health Optimization

Tsolmon Tsogbayar, MD

Tsolmon Tsogbayar, MD

Health Programs Lead, Health Innovation

Dr. Tsogbayar leverages her clinical expertise to develop innovative health solutions and evidence-based coaching. Dr. Tsogbayar previously practiced as a physician with a comprehensive training background, developing specialized expertise in cardiology and emergency medicine after gaining experience in primary care, allergy & immunology, internal medicine, and general surgery.

She earned her medical degree from Imperial College London, where she also completed her MSc in Human Molecular Genetics after obtaining a BSc in Biochemistry from Queen Mary University of London. Her academic research includes significant work in developmental cardiovascular genetics, with her thesis publication contributing to the understanding of genetic modifications on embryonic cardiovascular development.

View Details
Pavel Korecky, MD

Pavel Korecky, MD

Director of Product Operations

Director of Product Operations at SiPhox Health with a background in medicine and a passion for health optimization. Experienced in leading software and clinical development teams, developing MVPs, contributing to patents, and launching health-related products.

Skilled in product operations, technical and non-technical product development, and agile project management, with expertise in diagnostic and medical technology.

View Details
Paul Thompson, MD

Paul Thompson, MD

Advisor

Paul D. Thompson is Chief of Cardiology Emeritus of Hartford Hospital and Professor Emeritus at University of Connecticut Medical School. He has authored over 500 scientific articles on cardiovascular risk factors, the effects of exercise, and beyond. He received National Institutes of Health’s (NIH) Preventive Cardiology Academic Award, and has received NIH funding for multiple studies.

Dr. Thompson’s interests in exercise, general cardiology and sports cardiology originated from his own distance running: he qualified for the 1972 Olympic Marathon Trials as a 3rd year medical student and finished 16th in the 1976 Boston Marathon. Dr. Thompson publishes a blog 500 Rules of Cardiology where he shares lessons and anecdotes that he has learned over his extensive career as a physician, researcher and teacher.

View Details
Ben Bikman, PhD

Ben Bikman, PhD

Advisor

Benjamin Bikman earned his Ph.D. in Bioenergetics and was a postdoctoral fellow with the Duke-National University of Singapore in metabolic disorders. Currently, his professional focus as a scientist and professor (Brigham Young University) is to better understand the role of elevated insulin and nutrient metabolism in regulating obesity, diabetes, and dementia.

In addition to his academic pursuits, Dr. Bikman is the author of Why We Get Sick and How Not To Get Sick.

View Details
Tash Milinkovic, MD

Tash Milinkovic, MD

Health Programs Lead, Heart & Metabolic

Dr. Natasha Milinkovic is part of the clinical product team at SiPhox Health, having graduated from the University of Bristol Medical School. Her medical career includes rotations across medical and surgical specialties, with specialized research in vascular surgery, focusing on recovery and post-operative pain outcomes. Dr. Milinkovic built her expertise in emergency medicine as a clinical fellow at a major trauma center before practicing at a central London teaching hospital throughout the pandemic.

She has contributed to global health initiatives, implementing surgical safety standards and protocols across rural Uganda. Dr. Milinkovic initially joined SiPhox Health to spearhead the health coaching initiative and has been a key contributor in the development and launch of the Heart and Metabolic program. She is passionate about addressing health disparities by building scalable healthcare solutions.

View Details
Tsolmon Tsogbayar, MD

Tsolmon Tsogbayar, MD

Health Programs Lead, Health Innovation

Dr. Tsogbayar leverages her clinical expertise to develop innovative health solutions and evidence-based coaching. Dr. Tsogbayar previously practiced as a physician with a comprehensive training background, developing specialized expertise in cardiology and emergency medicine after gaining experience in primary care, allergy & immunology, internal medicine, and general surgery.

She earned her medical degree from Imperial College London, where she also completed her MSc in Human Molecular Genetics after obtaining a BSc in Biochemistry from Queen Mary University of London. Her academic research includes significant work in developmental cardiovascular genetics, with her thesis publication contributing to the understanding of genetic modifications on embryonic cardiovascular development.

View Details
Pavel Korecky, MD

Pavel Korecky, MD

Director of Product Operations

Director of Product Operations at SiPhox Health with a background in medicine and a passion for health optimization. Experienced in leading software and clinical development teams, developing MVPs, contributing to patents, and launching health-related products.

Skilled in product operations, technical and non-technical product development, and agile project management, with expertise in diagnostic and medical technology.

View Details
Paul Thompson, MD

Paul Thompson, MD

Advisor

Paul D. Thompson is Chief of Cardiology Emeritus of Hartford Hospital and Professor Emeritus at University of Connecticut Medical School. He has authored over 500 scientific articles on cardiovascular risk factors, the effects of exercise, and beyond. He received National Institutes of Health’s (NIH) Preventive Cardiology Academic Award, and has received NIH funding for multiple studies.

Dr. Thompson’s interests in exercise, general cardiology and sports cardiology originated from his own distance running: he qualified for the 1972 Olympic Marathon Trials as a 3rd year medical student and finished 16th in the 1976 Boston Marathon. Dr. Thompson publishes a blog 500 Rules of Cardiology where he shares lessons and anecdotes that he has learned over his extensive career as a physician, researcher and teacher.

View Details
Ben Bikman, PhD

Ben Bikman, PhD

Advisor

Benjamin Bikman earned his Ph.D. in Bioenergetics and was a postdoctoral fellow with the Duke-National University of Singapore in metabolic disorders. Currently, his professional focus as a scientist and professor (Brigham Young University) is to better understand the role of elevated insulin and nutrient metabolism in regulating obesity, diabetes, and dementia.

In addition to his academic pursuits, Dr. Bikman is the author of Why We Get Sick and How Not To Get Sick.

View Details
Tash Milinkovic, MD

Tash Milinkovic, MD

Health Programs Lead, Heart & Metabolic

Dr. Natasha Milinkovic is part of the clinical product team at SiPhox Health, having graduated from the University of Bristol Medical School. Her medical career includes rotations across medical and surgical specialties, with specialized research in vascular surgery, focusing on recovery and post-operative pain outcomes. Dr. Milinkovic built her expertise in emergency medicine as a clinical fellow at a major trauma center before practicing at a central London teaching hospital throughout the pandemic.

She has contributed to global health initiatives, implementing surgical safety standards and protocols across rural Uganda. Dr. Milinkovic initially joined SiPhox Health to spearhead the health coaching initiative and has been a key contributor in the development and launch of the Heart and Metabolic program. She is passionate about addressing health disparities by building scalable healthcare solutions.

View Details
Tsolmon Tsogbayar, MD

Tsolmon Tsogbayar, MD

Health Programs Lead, Health Innovation

Dr. Tsogbayar leverages her clinical expertise to develop innovative health solutions and evidence-based coaching. Dr. Tsogbayar previously practiced as a physician with a comprehensive training background, developing specialized expertise in cardiology and emergency medicine after gaining experience in primary care, allergy & immunology, internal medicine, and general surgery.

She earned her medical degree from Imperial College London, where she also completed her MSc in Human Molecular Genetics after obtaining a BSc in Biochemistry from Queen Mary University of London. Her academic research includes significant work in developmental cardiovascular genetics, with her thesis publication contributing to the understanding of genetic modifications on embryonic cardiovascular development.

View Details
Pavel Korecky, MD

Pavel Korecky, MD

Director of Product Operations

Director of Product Operations at SiPhox Health with a background in medicine and a passion for health optimization. Experienced in leading software and clinical development teams, developing MVPs, contributing to patents, and launching health-related products.

Skilled in product operations, technical and non-technical product development, and agile project management, with expertise in diagnostic and medical technology.

View Details
Paul Thompson, MD

Paul Thompson, MD

Advisor

Paul D. Thompson is Chief of Cardiology Emeritus of Hartford Hospital and Professor Emeritus at University of Connecticut Medical School. He has authored over 500 scientific articles on cardiovascular risk factors, the effects of exercise, and beyond. He received National Institutes of Health’s (NIH) Preventive Cardiology Academic Award, and has received NIH funding for multiple studies.

Dr. Thompson’s interests in exercise, general cardiology and sports cardiology originated from his own distance running: he qualified for the 1972 Olympic Marathon Trials as a 3rd year medical student and finished 16th in the 1976 Boston Marathon. Dr. Thompson publishes a blog 500 Rules of Cardiology where he shares lessons and anecdotes that he has learned over his extensive career as a physician, researcher and teacher.

View Details
Ben Bikman, PhD

Ben Bikman, PhD

Advisor

Benjamin Bikman earned his Ph.D. in Bioenergetics and was a postdoctoral fellow with the Duke-National University of Singapore in metabolic disorders. Currently, his professional focus as a scientist and professor (Brigham Young University) is to better understand the role of elevated insulin and nutrient metabolism in regulating obesity, diabetes, and dementia.

In addition to his academic pursuits, Dr. Bikman is the author of Why We Get Sick and How Not To Get Sick.

View Details
Tash Milinkovic, MD

Tash Milinkovic, MD

Health Programs Lead, Heart & Metabolic

Dr. Natasha Milinkovic is part of the clinical product team at SiPhox Health, having graduated from the University of Bristol Medical School. Her medical career includes rotations across medical and surgical specialties, with specialized research in vascular surgery, focusing on recovery and post-operative pain outcomes. Dr. Milinkovic built her expertise in emergency medicine as a clinical fellow at a major trauma center before practicing at a central London teaching hospital throughout the pandemic.

She has contributed to global health initiatives, implementing surgical safety standards and protocols across rural Uganda. Dr. Milinkovic initially joined SiPhox Health to spearhead the health coaching initiative and has been a key contributor in the development and launch of the Heart and Metabolic program. She is passionate about addressing health disparities by building scalable healthcare solutions.

View Details
Tsolmon Tsogbayar, MD

Tsolmon Tsogbayar, MD

Health Programs Lead, Health Innovation

Dr. Tsogbayar leverages her clinical expertise to develop innovative health solutions and evidence-based coaching. Dr. Tsogbayar previously practiced as a physician with a comprehensive training background, developing specialized expertise in cardiology and emergency medicine after gaining experience in primary care, allergy & immunology, internal medicine, and general surgery.

She earned her medical degree from Imperial College London, where she also completed her MSc in Human Molecular Genetics after obtaining a BSc in Biochemistry from Queen Mary University of London. Her academic research includes significant work in developmental cardiovascular genetics, with her thesis publication contributing to the understanding of genetic modifications on embryonic cardiovascular development.

View Details
Pavel Korecky, MD

Pavel Korecky, MD

Director of Product Operations

Director of Product Operations at SiPhox Health with a background in medicine and a passion for health optimization. Experienced in leading software and clinical development teams, developing MVPs, contributing to patents, and launching health-related products.

Skilled in product operations, technical and non-technical product development, and agile project management, with expertise in diagnostic and medical technology.

View Details
Paul Thompson, MD

Paul Thompson, MD

Advisor

Paul D. Thompson is Chief of Cardiology Emeritus of Hartford Hospital and Professor Emeritus at University of Connecticut Medical School. He has authored over 500 scientific articles on cardiovascular risk factors, the effects of exercise, and beyond. He received National Institutes of Health’s (NIH) Preventive Cardiology Academic Award, and has received NIH funding for multiple studies.

Dr. Thompson’s interests in exercise, general cardiology and sports cardiology originated from his own distance running: he qualified for the 1972 Olympic Marathon Trials as a 3rd year medical student and finished 16th in the 1976 Boston Marathon. Dr. Thompson publishes a blog 500 Rules of Cardiology where he shares lessons and anecdotes that he has learned over his extensive career as a physician, researcher and teacher.

View Details
Ben Bikman, PhD

Ben Bikman, PhD

Advisor

Benjamin Bikman earned his Ph.D. in Bioenergetics and was a postdoctoral fellow with the Duke-National University of Singapore in metabolic disorders. Currently, his professional focus as a scientist and professor (Brigham Young University) is to better understand the role of elevated insulin and nutrient metabolism in regulating obesity, diabetes, and dementia.

In addition to his academic pursuits, Dr. Bikman is the author of Why We Get Sick and How Not To Get Sick.

View Details
Tash Milinkovic, MD

Tash Milinkovic, MD

Health Programs Lead, Heart & Metabolic

Dr. Natasha Milinkovic is part of the clinical product team at SiPhox Health, having graduated from the University of Bristol Medical School. Her medical career includes rotations across medical and surgical specialties, with specialized research in vascular surgery, focusing on recovery and post-operative pain outcomes. Dr. Milinkovic built her expertise in emergency medicine as a clinical fellow at a major trauma center before practicing at a central London teaching hospital throughout the pandemic.

She has contributed to global health initiatives, implementing surgical safety standards and protocols across rural Uganda. Dr. Milinkovic initially joined SiPhox Health to spearhead the health coaching initiative and has been a key contributor in the development and launch of the Heart and Metabolic program. She is passionate about addressing health disparities by building scalable healthcare solutions.

View Details
Tsolmon Tsogbayar, MD

Tsolmon Tsogbayar, MD

Health Programs Lead, Health Innovation

Dr. Tsogbayar leverages her clinical expertise to develop innovative health solutions and evidence-based coaching. Dr. Tsogbayar previously practiced as a physician with a comprehensive training background, developing specialized expertise in cardiology and emergency medicine after gaining experience in primary care, allergy & immunology, internal medicine, and general surgery.

She earned her medical degree from Imperial College London, where she also completed her MSc in Human Molecular Genetics after obtaining a BSc in Biochemistry from Queen Mary University of London. Her academic research includes significant work in developmental cardiovascular genetics, with her thesis publication contributing to the understanding of genetic modifications on embryonic cardiovascular development.

View Details
Pavel Korecky, MD

Pavel Korecky, MD

Director of Product Operations

Director of Product Operations at SiPhox Health with a background in medicine and a passion for health optimization. Experienced in leading software and clinical development teams, developing MVPs, contributing to patents, and launching health-related products.

Skilled in product operations, technical and non-technical product development, and agile project management, with expertise in diagnostic and medical technology.

View Details
Paul Thompson, MD

Paul Thompson, MD

Advisor

Paul D. Thompson is Chief of Cardiology Emeritus of Hartford Hospital and Professor Emeritus at University of Connecticut Medical School. He has authored over 500 scientific articles on cardiovascular risk factors, the effects of exercise, and beyond. He received National Institutes of Health’s (NIH) Preventive Cardiology Academic Award, and has received NIH funding for multiple studies.

Dr. Thompson’s interests in exercise, general cardiology and sports cardiology originated from his own distance running: he qualified for the 1972 Olympic Marathon Trials as a 3rd year medical student and finished 16th in the 1976 Boston Marathon. Dr. Thompson publishes a blog 500 Rules of Cardiology where he shares lessons and anecdotes that he has learned over his extensive career as a physician, researcher and teacher.

View Details
Ben Bikman, PhD

Ben Bikman, PhD

Advisor

Benjamin Bikman earned his Ph.D. in Bioenergetics and was a postdoctoral fellow with the Duke-National University of Singapore in metabolic disorders. Currently, his professional focus as a scientist and professor (Brigham Young University) is to better understand the role of elevated insulin and nutrient metabolism in regulating obesity, diabetes, and dementia.

In addition to his academic pursuits, Dr. Bikman is the author of Why We Get Sick and How Not To Get Sick.

View Details
Tash Milinkovic, MD

Tash Milinkovic, MD

Health Programs Lead, Heart & Metabolic

Dr. Natasha Milinkovic is part of the clinical product team at SiPhox Health, having graduated from the University of Bristol Medical School. Her medical career includes rotations across medical and surgical specialties, with specialized research in vascular surgery, focusing on recovery and post-operative pain outcomes. Dr. Milinkovic built her expertise in emergency medicine as a clinical fellow at a major trauma center before practicing at a central London teaching hospital throughout the pandemic.

She has contributed to global health initiatives, implementing surgical safety standards and protocols across rural Uganda. Dr. Milinkovic initially joined SiPhox Health to spearhead the health coaching initiative and has been a key contributor in the development and launch of the Heart and Metabolic program. She is passionate about addressing health disparities by building scalable healthcare solutions.

View Details